Impact of left ventricular end-diastolic pressure as a marker for diastolic dysfunction on long-term outcomes in patients undergoing transcatheter aortic valve replacement
Related Experiment Video
Updated: Jul 11, 2025

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery
Published on: November 28, 2018
Mariia Emelianova1, Vanessa Sciacca2, Regine Brinkmann1
1Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum Nordrhein-Westfalen, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
Insights
Elevated left ventricular end-diastolic pressure (LVEDP) after transcatheter aortic valve replacement (TAVR) predicts long-term mortality. Pulmonary hypertension and tricuspid regurgitation also increase mortality risk in TAVR patients.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Medical Diagnostics
Background:
- Severe aortic stenosis necessitates transcatheter aortic valve replacement (TAVR).
- Diastolic function assessment is crucial for predicting outcomes post-TAVR.
- Left ventricular end-diastolic pressure (LVEDP) is a key hemodynamic parameter.
Purpose of the Study:
- To determine the prevalence of elevated post-TAVR LVEDP.
- To evaluate elevated LVEDP as a predictor of long-term mortality after TAVR.
- To identify other predictors of mortality in TAVR patients.
Main Methods:
- Retrospective analysis of 3328 patients undergoing TAVR.
- Stratification into normal (<15 mmHg) and elevated (≥15 mmHg) post-procedural LVEDP groups.
- Multivariate analysis to identify independent predictors of mortality.
Main Results:
- Elevated post-procedural LVEDP was observed in 72.3% of patients.
- Five-year mortality was significantly higher in the elevated LVEDP group (27.4% vs. 8.3%).
- Independent predictors of mortality included elevated LVEDP, tricuspid regurgitation, and pulmonary hypertension.
Conclusions:
- Elevated post-procedural LVEDP is an independent predictor of all-cause mortality post-TAVR.
- Pulmonary hypertension and tricuspid regurgitation also predict mortality.
- Diastolic dysfunction is a critical factor influencing TAVR outcomes and management decisions.
Objective:
The aim of this study was to investigate the proportion of elevated left ventricular end-diastolic pressure (LVEDP) as an indicator of diastolic function after transcatheter aortic valve replacement (TAVR) and its implication in predicting long-term mortality.
Methods:
We analyzed retrospectively collected data on 3328 patients with severe aortic stenosis undergoing TAVR in our institution between July 2009 and June 2021. Patients were stratified into two groups based on invasive post-procedural LVEDP measurements: normal (<15 mmHg) vs. elevated (≥15 mmHg) LVEDP.
Results:
Mean age of the patients was 81.6 years, and 53.3% were female. Elevated post-procedural LVEDP was identified in 2408 (72.3%) patients. The 5-year mortality rates were higher in the group with elevated LVEDP compared with the group with normal LVEDP (27.4% vs. 8.3%, p = 0.01; hazard ratio [HR] 1.22, 95% CI 1.05-1.41). A multivariate model revealed the following independent predictors of mortality after TAVR: post-procedural elevated LVEDP (HR 1.24, 95% CI 1.01-1.53), pre-procedural significant tricuspid regurgitation (HR 1.24, 95% CI 1.02-1.52) and pulmonary hypertension (PH) (HR 1.53, 95% CI 1.26-1.86). In the present study, a significant paravalvular leak after TAVR was not associated with higher mortality (HR 1.45, 95% CI-0.95-2.19, p = 0.75).
Conclusion:
Elevated post-procedural LVEDP in patients who undergo TAVR is an independent predictor of all-cause mortality. Furthermore, PH and tricuspid regurgitation were also identified as predictors of mortality. These data confirm that diastolic dysfunction is an important predictor of mortality in TAVR and should be considered to guide procedure timing, favoring an early interventional approach and management in aortic stenosis patients.
More Related Videos
Related Concept Videos
Aortic Regurgitation I: Introduction
Mitral Regurgitation I: Introduction
Aortic Regurgitation III: Medical Management
Mitral Stenosis I: Introduction
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Heart Failure II: Pathophysiology

